



Volume 25 Issue 4 (2014) 230 
Indonesian J. Pharm. Vol. 25 No. 4 : 230 – 236   
ISSN-p : 2338-9427 
DOI: 10.14499/indonesianjpharm25iss4pp230 
 
INTERACTION STUDY: THE EFFECT OF ORTHOSIPHON 
STAMINEUS EXTRACT ON HUMAN CYTOCHROME P450  
 
Purwantiningsih1*, Abas Hj Hussin2 
 
1Dept of Pharmacology and 
Clinical Pharmacy, Faculty 
of Pharmacy, Gadjah Mada 
University, Skip Utara, 
55281, Yogyakarta, 
Indonesia  
2Centre for Drug Research, 
Universiti Sains Malaysia, 













Herbal remedies are often used concomitantly with 
prescribed medication, which leads to an increase in the potential 
of herb-drug interactions. Orthosiphon stamineus is one of the 
popular herbal preparations that is traditionally used, especially as 
a diuretic or for the elimination of kidney stones. The inhibitory 
effect of O. stamineus extract on human cytochrome P450 
isoforms, namely CYP1A2, CYP3A4, CYP2C9 and CYP2D6, has 
been determined using luminescent methods. The final 
concentrations of O. stamineus extract tested were 0.01, 0.1, 1, 
10, 100 and 1000µg/mL. IC50 value was used to assess the 
modulation potencies for each CYP isoform. The extract showed a 
moderate inhibition towards CYP2C9 with the IC50 of 20.12µg/mL 
and showed IC50 of 49.90, 89.24 and 97.82µg/mL for CYP1A2, 
CYP2D6 and CYP3A4, respectively. These data suggest that O. 
stamineus extract may potentiate the herb-drug interaction via 
CYP inhibition. 
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INTRODUCTION 
Herbal preparations have been widely used 
in the world and the market has been rapidly 
growing in recent years. Orthosiphon stamineus Benth, 
belonging to the family Lamiceae, is one of the most 
popular medicinal plants in Southeast Asia, 
including Indonesia and Malaysia. O. stamineus is 
locally known as Misai Kucing or remujung, and has 
received great attention from researchers. The plant 
is used as an alternative medicine in Malaysia and 
has also been sold as a dietary supplement in recent 
years (Wiart, 2002). In many European countries, O. 
stamineus is consumed as a herbal tea to promote 
health due to its high antioxidant properties 
(Indubala and Ng, 2000). 
O. stamineus contains several chemically active 
constituents; one of the most important classes of 
compounds is the phenolic group. Some researchers 
have isolated many phenolic compounds including 
lipophilic flavones, flavonol glycosides, and caffeic 
acid derivatives, such as 2,3-dicaffeoyltartaric acid 
and rosmarinic acid, which have been identified and 
quantified by High Performance Liquid 
Chromatography (Sumaryono et al., 1991). O. 
stamineus leaves contain polymethoxylated flavones, 
sinensetin, tetramethylscutellarein and 30-hydroxy-
5,6,7,40-tetramethoxyflavone, as reported by Pietta 
et al. (1998). Other researchers (Tezuka et al., 2000) 
found the chemical constituents of O. stamineus to 
include caffeic acid derivatives, diterpene esters, 
triterpene saponins, flavonoids, antioxidants and 
volatile oil. 
A number of interaction studies of O. 
Stamineus have been published. Chin et al. (2009) 
reported that methanol leaf extracts of O. Stamineus 
increased both UGT and GST activity in the 
diabetic rat liver. An in vitro inhibitory study of O. 
Stamineus on UGT isoforms showed that the extract 
inhibited UGT1A9, UGT1A1, UGT1A6 and 
UGT1A8 with an IC50 of 10.83, 24.65, 30.02 and 
43.39µg/mL, respectively. However, the extract 
showed an IC50 of more than 50µg/mL for 
UGT1A3, UGT1A10, UGT2B7 and UGT2B15 
activities (Ismail et al., 2010). Chin and Hussin 
(2011) reported that O. Stamineus increased 
aminopyrine metabolism by inhibiting protein 
kinase-A in female rat hepatocytes. 
The use of herbal remedies that are often co-
administered with prescribed drugs has led to an 
increase in herb-drug interactions (Zhou et al., 2004). 
These herb-drug interactions have a high prevalence 
but are often unknown, which signifies negligence 
of consumers with regard to reporting herb-drug 
interactions or adverse reactions when taking herbal 
medicines (Barnes et al., 1998). There are many 
reports that provide evidence for clinically 
important herb-drug interactions, where the 
concurrent use of herbal medicines with synthetic 
drugs is noted (Fugh-Berman, 2000).  
The herb-drug interactions may occur with 
the use of O. stamineus and prescribed drugs since 
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the herb is commonly used to treat diabetes mellitus, 
hypertension and gout problems in many Southeast 
Asia countries (Wiart, 2002). The interaction may 
occur during the pharmacokinetic phase, which 
includes absorption, distribution, metabolism or 
excretion processes, and also in the 
pharmacodynamic phases (Izzo et al., 2002). 
Alteration of drug concentrations by the concurrent 
use of herbal medicines may occur through the 
inhibition or induction of hepatic drug-metabolizing 
enzymes, especially the cytochrome P450s (CYP) 
(Wilkinson, 1997; Ioannides, 2002; Zhou et al., 
2003). The aim of this study was to examine the 
effect of O. stamineus on the activities of human 
CYP450 isoforms, especially CYP1A2, CYP2C9, 
CYP2D6 and CYP3A4.  
 
MATERIALS AND METHODS 
Reagents 
The luminescence assay was performed 
according to Hanapi et al. (2010), using a 96-
well microtiter plate using the P450-GLOTM 
Screening System from Promega®, USA 
(Thermo Scientific®, Finland). The screening 
systems included the four sub-types of CYP450 
(CYP 1A2, 2C9, 2D6 and 3A4) and 4 different 
substrates were used in these experiments: 
luciferin 6’ methyl ether (luciferin-ME) for 
CYP1A2 and 6’ deoxyluciferin (luciferin-H) for 
CYP2C9, and the ethylene glycol ester of 
luciferin 6’ methyl ether (luciferin-H EGE) and 
luciferin 6’ benzyl ether (luciferin-BE) for 
CYP2D6 and CYP3A4, respectively. Each 
system contained the luciferin detection 
reagent, the CYP membranes and control 
membranes, the solution A and B of the 
NADPH regeneration system, 1M potassium 
phosphate buffer and luciferin-free water. Four 
known positive controls, sulfaphenazole, alpha 
naphtoflavone, quinidine and ketoconazole, 




The O. stamineus extract was provided by 
Prof. Zhari Ismail from the School of 
Pharmaceutical Sciences, Universiti Sains 
Malaysia. The extract was obtained according to 
the previous study. O. stamineus leaves were 
collected in the afternoon, from plants aged 30 
to 45 days, white flowered plants and the 
voucher specimens of plant material were 
deposited at Bilik Herba, School of 
Pharmaceutical Sciences, Universiti Sains 
Malaysia. Methanol extraction of O. stamineus 
was performed by extracting the dried leaves 
(10g) with 100mL of methanol at 
approximately 40°C for 4 hours with 
continuous stirring. The extract was filtered 
through Whatman filter paper (No. 1), and then 
concentrated and spray-dried to obtain the 
crude methanol extract (Akowuah et al., 2004). 
 
Luciferin standard curve preparation 
Luciferin standard curve of each CYP 
was performed by preparing the D-luciferin 
stock solutions at concentration of 2mM. Then, 
a serial dilution concentration of D-luciferin 
standard (four times concentration) was made 
to obtain the standard solutions with final 
concentrations of 2µM, 0.4µM, 0.08µM and 
0.016µM. The reaction mixture and reaction 
control mixture for each CYP (CYP1A2, 
CYP3A4, CYP2C9 or CYP2D6) were prepared 
at four times concentrations, while the 
NADPH regeneration system was prepared at a 
two times concentration. The reaction was 
started by adding 12.5µL of D-luciferin 
standards into a 96-well white opaque plate in 
the appropriate wells; in the 0µM D-luciferin 
wells, 12.5µL of luciferin-free water was added. 
The control reaction mixture (12.5µL) was then 
added and the plate was shaken by tapping the 
plate carefully. The reaction system was pre-
incubated for 10min at 27ºC and 25µL of CYP 
NADPH regeneration system was added to 
each well. The plate was tapped again and 
incubated for 30min at 27ºC. The reconstituted 
luciferin detection reagent (50µL) was added to 
all of the wells, was briefly mixed and then 
incubated for 20min at 27ºC to stabilize the 
luminescent signal. The signal was recorded 
using a plate-reading luminometer (Hidex Plate 
CHAMELEON®, Hidex Oy, USA) and the 




The enzyme assay was performed by 
adding the test compound of O. stamineus 
solution (12.5µL) with concentrations ranging 
from 0.01 to 1000µg/mL or the positive 
control solution ranging from 0.02 to 200µM to 
the wells of a microtiter plate. In the untreated 
wells,  the test compound was replaced with the 
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12.5µL of luciferin-free water. Then, 12.5µL of 
the control reaction mixture was added and the 
reaction was continued as described in section 
“luciferin standard curve preparation”. 
 
Data analysis 
The data are presented as percentage of 
activity compared to the blank group and         
the IC50 was determined to examine the 
inhibitory potency of O. stamineus extract and 
the positive control on cytochrome P450 
enzyme activity. 
 
RESULTS AND DISCUSSION 
This interaction study used four human 
CYP450 isoforms namely CYP1A2, CYP3A4, 
CYP2D6 and CYP2C9 to examine the effect of 
O. stamineus and positive control on the enzyme 
activities using a luminescent assay. Alpha 
naphtoflavone, ketoconazole, quinidine and 
sulphaphenazole were used as positive control 
towards CYP1A2, CYP3A4, CYP2D6 and 
CYP2C9, respectively. In this assay, beetle 
luciferin was taken as a luminogenic P450 
probe substrates. Beetle luciferin would be 
converted by different P450 enzymes to 
luciferin. Then, the luciferase enzyme will 
create light from the free luciferin as a substrate 
and supported by ATP and oxygen. The light 
produced is directly proportional to the activity 
of CYP450 enzyme and was measured using a 
microplate reader. Luminescent assay is more 
profitable as compared to the fluorescent assay, 
because there has no fluorescent interferences 
(Bosetti et al., 2005) 
Interaction results of O. stamineus and the 
positive control towards four CYP450 isoforms 
are shown in Figure 1-4, while the IC50 results 
are shown in Table I. The methanol extract of 
O. stamineus showed an inhibitory effect on 
CYP450 activities, with the highest inhibition 
towards CYP2C9 and has an IC50 at 
20.12µg/mL. The O. stamineus’s IC50 was greater 
if compared to sulphapenazole as positive 
control with an IC50 at 0.03µg/mL (Figure 1). 
The same phenomena were also found in the 
interaction results of O. stamineus extract 
towards CYP1A2, CYP2D6 and CYP2C9 
activities with IC50 values of 49.90µg/mL, 
89.24µg/mL and 97.82µg/mL, respectively. 
The positive control showed the IC50 values of 
0.007µg/mL, 2.9µg/mL and 0.003µg/mL, 
correspondingly (Figure 2-4). These findings 
suggest that these plants showed a weak 
inhibition compared to the positive control. 
This may because the extract contained many 
compounds so that the interaction with each 
CYP450 was not specific. 
The O. stamineus extract was reported to 
possess rosmarinic acid as the main 
component, with concentrations ranging from 
5.1% to 29.9% of the total dry leaf weight; also, 
this extract contained 3’-hydroxy-5, 6, 7, 4’-
tetramethoxyflavone, eupatorin and sinensetin, 
with levels ranging from 0.05% to 0.69%, 
0.34% to 3.37% and 0.22% to 1.76%, 
respectively. Thus, it has great potential for 
commercialization due to the high medicinal 





Figure 1. Effect of O. stamineus (A) and Sulphaphenazole (B) on the CYP2C9 activity. 
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Interactions between herbal remedies 
and CYP isoforms (CYPs) have been assessed 
and a number of studies have been published. 
For example, the inhibitory effects of 
asiaticoside and madecassoside on human 
CYPs were studied by Winitthana et al. (2011). 
The results showed that asiaticoside inhibited 
CYP2C19 and CYP3A4. Madecassoside also 
inhibited CYP2C19 and CYP3A4, but both 
asiaticoside and madecassoside had no effect 
on the activities of CYP1A2, CYP2C9 and 
CYP2D6 and CYP2E1. Ohnishi et al. (2000) 
reported the effect of furanocoumarin 
derivatives in grapefruit juice on the activity of 
cytochrome P450 3A4; dihydroxybergamottin, 
bergamottin and bergapten showed potent 
inhibition with IC50 ranging from 0.075 to 1.0 
µM. In another study, the effects of St John's 
wort (Hypericum perforatum) on human 
cytochrome P450 activity were investigated by 
Wang et al. (2001); the results indicated that St 
John’s wort was a selective inductor for 
CYP3A, but did not alter the CYP1A2, 
CYP2C9 and CYP2D6 activities after St John’s 
wort was administered.  
There are a lot of medicinal plants that 
have been used either in primary forms or 
combined into mixtures as traditional 
medicines. Traditional medicine has been 
assumed to be non-toxic because the 
compounds originate from natural sources 
(Zhou et al., 2004). Pharmacologically active 
constituents such as alkaloids, flavonoids, 
terpenoids, polyphenols, anthraquinones, 
glycosides, saponins, coumarins, tannins and 
essential oils can be found in plants and have 
the ability to promote herb-drug interactions 
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Intestinal PgP and CYP3A4 have an 
important role in determining many drugs’ 
bioavailability. The modulation of CYP3A and 
intestinal PgP constitutes an important 
mechanism of increasing or decreasing the 
concomitant drug bioavailability (Fugh-
Berman, 2000; Fugh-Berman and Ernst, 2001; 
Izzo and Ernst, 2001). The interaction of O 
stamineus extract with CYP2C9 and CYP1A2 
induced moderate inhibition towards the two 
CYPs (Qiu et al., 2008), suggesting that the 
extract may modulate the metabolism of drugs 
metabolized by CYP2C9 and CYP1A2. It has 
been estimated that CYP2C9 is responsible for 
the metabolic clearance of up to 15-20% of all 
drugs undergoing phase I metabolism (Booven 
et al., 2010), while the cytochrome CYP1A2 
plays a major role in the metabolism of many 
drugs that commonly clinical used (5-10%). 
 
CONCLUSION  
The standardized extract of O. stamineus 
showed moderate inhibition towards CYP2C9 
and CYP1A2 with IC50 values of 20.12 µg/mL 
and 49.90 µg/mL. While interaction study with 
CYP2D6 and CYP3A4 showed inhibition with 
IC50 values of 89.24 and 97.82 µg/mL, 
respectively. These data suggested that O. 
stamineus extract may induce herb-drug 
interactions, since the CYP2C9 or CYP1A2  
isoforms are responsible for the metabolism of 
many drugs. 
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